U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H24N2OS.C4H4O4
Molecular Weight 456.555
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PROPIOMAZINE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CC(C)N(C)C)C2=C1

InChI

InChIKey=ILEKKZUHFYUQIE-BTJKTKAUSA-N
InChI=1S/C20H24N2OS.C4H4O4/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20;5-3(6)1-2-4(7)8/h6-12,14H,5,13H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C20H24N2OS
Molecular Weight 340.482
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Propiomazine is a typical antipsychotic, blocking H1 receptors and is primarily indicated in conditions Insomnia. Propiomazine was also used under brand name largon for the relief of restlessness and apprehension, preoperatively or during surgery. In addition largon was used as an adjunct to analgesics for the relief of restlessness and apprehension during labor. But this drug was discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL231
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
LARGON

Approved Use

Unknown

Launch Date

-2.86329602E11
Palliative
LARGON

Approved Use

Unknown

Launch Date

-2.86329602E11
Primary
Unknown

Approved Use

Unknown
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.7 h
20 mg single, intravenous
dose: 20 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PROPIOMAZINE serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
10.8 h
single, intramuscular
PROPIOMAZINE serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
8.6 h
single, oral
PROPIOMAZINE serum
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
19%
PROPIOMAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Citalopram in fatal poisoning cases.
2002 Mar 28
Mucosal delivery of cytotoxic therapeutic agents: response of rat nasal mucosa to microencapsulated ethopropazine HCl enantiomer.
2005 Nov
[Treatment of sleep disorders during pregnancy and breast feeding].
2006 Oct 4-10
Are sedatives and hypnotics associated with increased suicide risk of suicide in the elderly?
2009 Jun 4
Socioeconomic determinants of psychotropic drug utilisation among elderly: a national population-based cross-sectional study.
2010 Mar 9
Patents

Patents

Sample Use Guides

Usual adult dose: Preoperative: intramuscular or intravenous: 20 to 40 mg administered in conjunction with 50 mg of meperidine. Sedation during surgery with local, nerve block, or spinal anesthesia: intramuscular or intravenous 10 to 20 mg. Analgesia adjunct, during labor: intramuscular or intravenous, 20 to 40 mg in the early stages of labor, then 20 to 40 mg of propiomazine administered in conjunction with 25 to 75 mg of meperidine when labor is definitely established. Doses may be repeated every three hours, if necessary. Usual pediatric dose: sedation prior to surgery: preanesthetic or postoperative: children up to 27 kg: Intramuscular or intravenous, 550 mcg (0.55 mg) to 1.1 mg per kg of body; children 2 to 4 years of age: Intramuscular or intravenous, 10 mg; children 4 to 6 years of age: Intramuscular or intravenous, 15 mg; children 6 to 12 years of age: Intramuscular or intravenous, 25 mg. insomnia: 25 to 50 mg oral
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 04:41:35 UTC 2023
Edited
by admin
on Sat Dec 16 04:41:35 UTC 2023
Record UNII
OEY0ZC43SA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROPIOMAZINE MALEATE
WHO-DD  
Common Name English
PROPIOMAZINE MONOMALEATE
Common Name English
1-PROPANONE, 1-(10-(2-(DIMETHYLAMINO)PROPYL)-10H-PHENOTHIAZIN-2-YL)-, (2Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
Propiomazine maleate [WHO-DD]
Common Name English
DOREVANE
Brand Name English
INDORM
Brand Name English
1-PROPANONE, 1-(10-(2-(DIMETHYLAMINO)PROPYL)-10H-PHENOTHIAZIN-2-YL)-, (±)-, (2Z)-2-BUTENEDIOATE (1:1)
Common Name English
Code System Code Type Description
CAS
3568-23-8
Created by admin on Sat Dec 16 04:41:36 UTC 2023 , Edited by admin on Sat Dec 16 04:41:36 UTC 2023
PRIMARY
ECHA (EC/EINECS)
222-661-6
Created by admin on Sat Dec 16 04:41:36 UTC 2023 , Edited by admin on Sat Dec 16 04:41:36 UTC 2023
PRIMARY
EVMPD
SUB04084MIG
Created by admin on Sat Dec 16 04:41:36 UTC 2023 , Edited by admin on Sat Dec 16 04:41:36 UTC 2023
PRIMARY
FDA UNII
OEY0ZC43SA
Created by admin on Sat Dec 16 04:41:36 UTC 2023 , Edited by admin on Sat Dec 16 04:41:36 UTC 2023
PRIMARY
SMS_ID
100000091522
Created by admin on Sat Dec 16 04:41:36 UTC 2023 , Edited by admin on Sat Dec 16 04:41:36 UTC 2023
PRIMARY
PUBCHEM
5702109
Created by admin on Sat Dec 16 04:41:36 UTC 2023 , Edited by admin on Sat Dec 16 04:41:36 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY